Skip to main content

Foundational Leadership in Gastroenterology Research

With our history rooted in gastroenterology research, we have a proven track record in accelerating the research process in complex gastrointestinal disorders. Partnered with our country’s top gastroenterologists, our clinical research centers offer personalized care and access to new cutting-edge treatment options.


Doctor helping patient

Bringing Emerging Science to Patients

Our gastroenterology research has a scientific focus on various gastrointestinal disorders and liver diseases, which affect 2.6 billion and 1.5 billion people worldwide, respectively. Our integrated research approach creates an opportunity for our partnered physicians to pursue initial therapies for these prevalent diseases and offer cutting-edge treatment options to their patients, all while advancing science at the point of care.


Our Gastroenterology Research Areas

Our gastroenterology research is focused on the most prevalent GI that have a worldwide impact:

impacted by

Nonalcoholic fatty Liver Disease

impacted by

Nonalcoholic Steatohepatitis

impacted by

Irritable Bowel Syndrome

impacted by

Inflammatory Bowel Disease

impacted by

Celiac Disease

impacted by

Eosinophilic Disorders

The Growing NASH Epidemic

Nonalcoholic steatohepatitis (NASH) is a silent chronic disease that remains asymptomatic until the complications of liver cirrhosis are manifested.

Health Economic Icon
Health and economic epidemic.

NASH impacts 30 million people in the United States and is now the leading indication for liver transplantation. Today, we’re spending $5 billion annually in healthcare costs related to the disease. By 2030, this could rise to $30 billion.

Healthcare Workers
chronic disease.

NASH is a silent chronic disease that is often diagnosed only when patients develop signs of advanced liver disease. Many will also develop the advanced form of NASH, which can lead to cirrhosis, liver failure and a risk for liver cancer.

Early Detection Icon
Early detection
is key.

Utilizing ObjectiveHealth’s digital health technology, we accelerate the identification of potential NASH patients based on certain risk factors, such as diabetes, hypertension, and obesity, and recommend they undergo additional screening.

How ObjectiveHealth is Easing the Burden

While we work through clinical trials in pursuit of initial therapies, our research platform creates more regular, face-to-face patient care and monitoring. We promote lifestyle and diet changes that can have an immediate positive impact once a patient is diagnosed. Through our research partnerships, we are playing a major role in discovering the first available treatments for those eagerly anticipating new therapeutic discoveries.


Accelerating Research through Digital Health Technology

By utilizing our unique integrated electronic health record access, we apply ObjectiveHealth technology and health algorithms to find the right gastroenterology patients for the right trials, optimize trial outcomes, and better support patients in trial participation. This increases patient engagement, identifies disease progression early, and improves health outcomes.

Learn More